NEW YORK (GenomeWeb) – Bioinformatics software provider Genialis has raised $2.3 million in a recently closed seed round that was co-led by Zurich, Switzerland-based Redalpine Venture Capital and Boston's First Star Venture Capital.
Other investors in the round include Slovenian firm Pikas as well as several unnamed angel investors, according to Genialis.
The company said that it plans to use the funds to expand its US-based team as well as to commercialize the Genialis platform, which provides cloud-based software for visualizing and exploring next-generation sequencing data.
Earlier this year, Genialis began rolling out its software-as-a-service product line which is based on Expressions, its flagship suite for exploring RNA-sequencing data. The company also partnered with Swift Biosciences to launch a tailored application for variant discovery with targeted genome sequencing data.
Early access users of the company's Expressions software and its variant discovery apps include researchers from Harvard University, California Pacific Medical Center Research Institute, Johns Hopkins University, and Jackson Labs. The company has also signed a partnership with Baylor College of Medicine to provide an enterprise iteration of its platform that offers analysis workflows and additional data management and dissemination tools.
In a statement Christopher Mason, an associate professor at Weill Cornell Medicine and one of Genialis' scientific advisors, said the company's technology "does a great job of visualizing volumes of information in a dynamic, intuitive way" thus "eliminating a key barrier for many biologists interpreting their sequencing results and related data."